IP Library › Granted Patent US 11,359,015

Granted Patent B2

US 11,359,015 · App. 15/744,317 · Granted Jun 14, 2022

Humanized or chimeric CD3 antibodies

Inventors: Rik Rademaker (Utrecht, NL); Isil Altintas (Utrecht, NL); Patrick Engelberts (Utrecht, NL); Janine Schuurman (Utrecht, NL); Paul Parren (Utrecht, NL)

Assignee: GENMAB A/S

C07K16/2809 C07K16/32 A61K2039/505 C07K2317/24 C07K2317/31 C07K2317/526 C07K2317/55 C07K2317/565 C07K2317/73 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,359,015
App. No.: 15/744,317
Granted: Jun 14, 2022
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Claims (60)

1. A humanized or chimeric antibody which binds to human CD3, wherein said antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein:

a) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 176, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively;

b) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 184, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively; or

c) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 220, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively;

d) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 236, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively; or

e) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 244, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively.

2. The antibody according to claim 1 , wherein the antibody comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:s 1, 2, and 176, respectively, and a VL comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively.

3. The antibody according to claim 1 , wherein the antibody is a full-length antibody.

4. The antibody according to claim 1 , wherein the antibody is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

5. The antibody according to claim 1 , wherein the antibody is monovalent, bivalent or multivalent.

6. The antibody according to claim 1 , wherein said antibody comprises an Fc region comprising a first and a second immunoglobulin heavy chain.

7. The antibody according to claim 1 , wherein said antibody comprises a first and a second immunoglobulin heavy chain, wherein in at least one of said first and second immunoglobulin heavy chains one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

8. The antibody according to claim 7 , wherein in at least one of said first and second immunoglobulin heavy chains,

(a) the amino acid in the position corresponding to position D265 in a human IgG1 heavy chain is not D;

(b) the amino acid in the position corresponding to position N297 in a human IgG1 heavy chain is not N;

(c) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are not L and L, respectively;

(d) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E; or A and A, respectively;

(e) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E, respectively;

(f) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are A and A, respectively;

(g) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are not L, L, and D, respectively;

(h) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A; or A, A, and A, respectively;

(i) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A, respectively;

(j) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain, are A, A, and A, respectively; or

(k) the amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain are F, E, A, Q, and S, respectively.

9. A composition comprising the antibody of claim 1 and a carrier.

10. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutical acceptable carrier.

11. A diagnostic composition comprising the antibody according to claim 1 .

12. A kit for detecting the presence of CD3 antigen, or a cell expressing CD3, in a sample comprising

i) the antibody according to claim 1 ; and

ii) instructions for use.

13. A humanized or chimeric antibody which binds to human CD3, wherein the antibody comprises:

a) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 177 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,

b) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 185 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,

c) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 221 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,

d) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 237 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8, or

e) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 245 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8.

14. The antibody according to claim 13 , wherein the antibody comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 177 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8.

15. The antibody according to claim 13 , wherein the antibody is a full-length antibody.

16. The antibody according to claim 13 , wherein the antibody is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

17. The antibody according to claim 13 , wherein the antibody is monovalent, bivalent or multivalent.

18. The antibody according to claim 13 , wherein said antibody comprises an Fc region comprising a first and a second immunoglobulin heavy chain.

19. The antibody according to claim 13 , wherein said antibody comprises a first and a second immunoglobulin heavy chain, wherein in at least one of said first and second immunoglobulin heavy chains the amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

20. The antibody according to claim 19 , wherein in at least one of said first and second immunoglobulin heavy chains,